The field is genuinely advancing, and it is also genuinely oversold. The way to hold both facts at once is to sort every claim you encounter into one of three tiers.
Three Tiers, and Why They Matter
Most confusion about stem cells comes from treating one word as one thing. In practice there are established therapies with regulatory approval and outcome data, investigational therapies under active study with partial evidence, and claims with no credible support at all.
Knowing which tier a proposal sits in tells you what to expect, what to ask, and how sceptical to be about the language used to describe it.
Tier One: Established and Curative
Haematopoietic stem cell transplantation is the oldest and most consequential cell therapy in medicine. Used for defined blood cancers and blood disorders, it can be curative — and it is a demanding hospital procedure with significant risk, delivered by transplant teams over weeks, not an outpatient infusion.
Limbal stem cell grafting restores the corneal surface after certain chemical and thermal injuries, with durable results in appropriately selected eyes. A small group of approved cell and gene therapies — including CAR-T for specific haematological malignancies and gene-modified cell products for some inherited disorders — also sit here, each within strict indications.
What unites tier one is that the evidence came first and the approval followed.
Tier Two: Investigational but Actively Studied
This is where most of what patients travel for actually sits. Mesenchymal stem cell protocols are studied for osteoarthritis and joint degeneration, selected autoimmune conditions, graft-versus-host disease, and some neurological, respiratory and metabolic conditions. Trials report improvements in pain, inflammatory markers and function in a proportion of patients, with the usual caveats: small samples, varied protocols, inconsistent outcome measures and limited long-term follow-up.
The realistic aim in this tier is measurable improvement over a defined period, not cure and not organ repair. It is a legitimate aim — reduced pain and better function change how people live — but it needs to be stated honestly, including the possibility of no response.
Our joint pain and autoimmune pages describe what tier-two treatment is actually aiming at, and how physicians weigh it against conventional care.
Tier Three: Marketing, Not Medicine
Reversing ageing. Regrowing organs. Curing chronic disease in a single infusion. Resetting the immune system permanently. Nothing in the 2026 literature supports these claims, and their persistence in advertising says more about demand than about science.
A useful test: tier-three language is always about the cells and never about you. It describes what stem cells can supposedly do in general, rather than what this protocol is expected to change in your specific diagnosis, and by how much.
What Has Actually Changed by 2026
The meaningful progress of recent years has been less glamorous than the headlines: better characterisation of cell products, more consistent release testing, clearer dosing rationale, and more trials with longer follow-up. Cell and gene therapy approvals have expanded in haematology and in a small number of inherited conditions.
What has not changed is the boundary. Mesenchymal therapy for common chronic conditions remains investigational, and the honest description of it in 2026 is the same as it was in 2024 — promising in parts, unproven overall, and appropriate only for carefully selected patients.
Applying This to Your Own Decision
When a provider describes a treatment, ask which tier it belongs to and ask them to say so in writing. Ask what measurable change they expect, over what period, and what the plan is if nothing changes. A programme that can answer those three questions is operating clinically.
For the narrower question of which diseases can genuinely be cured, see what diseases can be cured using stem cells.
Ask Which Tier Your Condition Falls Into
Send your diagnosis and recent imaging and our medical team will tell you what is realistic — including when the answer is that treatment is not appropriate. Learn more about MRC Healthcare or arrange a consultation.
Schedule a Consultation
